WHO ICTRP trial
Phase III trial exploring the combination of bevacizumab and lomustine in…
NL-OMON39944 · Overview of Medical Research in the Netherlands (NL-OMON) · Not Recruiting
Key facts
| Trial ID | NL-OMON39944 |
|---|---|
| Public title | Phase III trial exploring the combination of bevacizumab and lomustine in patients with first recurrence of a glioblastoma |
| Scientific title | Phase III trial exploring the combination of bevacizumab and lomustine in patients with first recurrence of a glioblastoma - EORTC 26101 |
| Primary sponsor | European Organisation for Research in Treatment of Cancer (EORTC) |
| Registry | Overview of Medical Research in the Netherlands (NL-OMON) |
| Recruitment status | Not Recruiting |
| Study type | Interventional |
| Phase | 3 |
| Countries | Austria;Belgium;France;Germany;Italy;Netherlands ;Switzerland;United Kingdom |
| Conditions | GBM glioblastoma;10029211;glioblastoma |
| Interventions | Arm a: Lomustine 90 mg/m² every 6 weeks (cap. 160 mg) + bevacizumab 10 mg/kg every 2 weeks. until progression Arm b (control arm): Lomustine single agent 110 mg/m² every 6 weeks until progression… |
| Registration date | Apr 24, 2014 |
| Target size | 155 |
| Secondary IDs | 2010-023218-30;NCT01290939;NL36562.078.11 |
| Registry page | onderzoekmetmensen.nl |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: